NCT05821686View on ClinicalTrials.gov

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 2, 2026

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Human Interleukin-2 (IL-2) (Proleukin)

All the recruited participants will receive 4 intralesional injections of Interleukin-2 with a dose of 500,000 international units (IU) per mm width of tumor to max dose of 10 million IU.

All Listed Sponsors
lead

Nova Scotia Health Authority

OTHER